Reirradiation to the pelvis for recurrent rectal cancer

Woong Sub Koom, Yunseon Choi, Su Jung Shim, Jihye Cha, Jinsil Seong, Nam Kyu Kim, Ki Chang Nam, Ki Chang Keum

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objectives This study investigated late toxicity and infield progression-free survival in patients with locally recurrent rectal cancer (LRRC) who had previously received irradiation to the pelvis. Methods Twenty-two patients were treated by reirradiation to the pelvis between January 2000 and August 2007. All patients received curative surgery with preoperative or postoperative chemoradiotherapy as an initial treatment. Five patients (23%) underwent surgical resection after reirradiation. The median follow-up duration was 20 months (range, 7-91 months). Results Two patients (9%) had grade-3 acute toxicity and eight patients (36%) had grade-3 to -4 late toxicity. The incidence of grade-3 to -4 late toxicity in the gastrointestinal and urinary system was 18% and 27%, respectively. Recurrent tumor location (axial or anterior) and surgical resection after reirradiation significantly influenced severe late toxicity (P=0.024 and P=0.039, respectively). In the 17 patients not undergoing surgery after reirradiation, median infield progression-free survival was 16 months. Reirradiation doses exceeding 50Gyαβ10 (equivalent dose in 2Gy fractions) significantly increased the infield progression-free survival (P=0.005). Conclusions Tumor location (axial or anterior) and surgery after reirradiation may increase severe late toxicity. In addition, an EQD2 exceeding 50Gyαβ10 may improve infield control.

Original languageEnglish
Pages (from-to)637-642
Number of pages6
JournalJournal of surgical oncology
Volume105
Issue number7
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Rectal Neoplasms
Pelvis
Disease-Free Survival
Chemoradiotherapy
Re-Irradiation
Neoplasms
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Koom, Woong Sub ; Choi, Yunseon ; Shim, Su Jung ; Cha, Jihye ; Seong, Jinsil ; Kim, Nam Kyu ; Nam, Ki Chang ; Keum, Ki Chang. / Reirradiation to the pelvis for recurrent rectal cancer. In: Journal of surgical oncology. 2012 ; Vol. 105, No. 7. pp. 637-642.
@article{94a9ba83c8f9423ab1d64c1120cfc506,
title = "Reirradiation to the pelvis for recurrent rectal cancer",
abstract = "Objectives This study investigated late toxicity and infield progression-free survival in patients with locally recurrent rectal cancer (LRRC) who had previously received irradiation to the pelvis. Methods Twenty-two patients were treated by reirradiation to the pelvis between January 2000 and August 2007. All patients received curative surgery with preoperative or postoperative chemoradiotherapy as an initial treatment. Five patients (23{\%}) underwent surgical resection after reirradiation. The median follow-up duration was 20 months (range, 7-91 months). Results Two patients (9{\%}) had grade-3 acute toxicity and eight patients (36{\%}) had grade-3 to -4 late toxicity. The incidence of grade-3 to -4 late toxicity in the gastrointestinal and urinary system was 18{\%} and 27{\%}, respectively. Recurrent tumor location (axial or anterior) and surgical resection after reirradiation significantly influenced severe late toxicity (P=0.024 and P=0.039, respectively). In the 17 patients not undergoing surgery after reirradiation, median infield progression-free survival was 16 months. Reirradiation doses exceeding 50Gyαβ10 (equivalent dose in 2Gy fractions) significantly increased the infield progression-free survival (P=0.005). Conclusions Tumor location (axial or anterior) and surgery after reirradiation may increase severe late toxicity. In addition, an EQD2 exceeding 50Gyαβ10 may improve infield control.",
author = "Koom, {Woong Sub} and Yunseon Choi and Shim, {Su Jung} and Jihye Cha and Jinsil Seong and Kim, {Nam Kyu} and Nam, {Ki Chang} and Keum, {Ki Chang}",
year = "2012",
month = "6",
day = "1",
doi = "10.1002/jso.23023",
language = "English",
volume = "105",
pages = "637--642",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "7",

}

Koom, WS, Choi, Y, Shim, SJ, Cha, J, Seong, J, Kim, NK, Nam, KC & Keum, KC 2012, 'Reirradiation to the pelvis for recurrent rectal cancer', Journal of surgical oncology, vol. 105, no. 7, pp. 637-642. https://doi.org/10.1002/jso.23023

Reirradiation to the pelvis for recurrent rectal cancer. / Koom, Woong Sub; Choi, Yunseon; Shim, Su Jung; Cha, Jihye; Seong, Jinsil; Kim, Nam Kyu; Nam, Ki Chang; Keum, Ki Chang.

In: Journal of surgical oncology, Vol. 105, No. 7, 01.06.2012, p. 637-642.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reirradiation to the pelvis for recurrent rectal cancer

AU - Koom, Woong Sub

AU - Choi, Yunseon

AU - Shim, Su Jung

AU - Cha, Jihye

AU - Seong, Jinsil

AU - Kim, Nam Kyu

AU - Nam, Ki Chang

AU - Keum, Ki Chang

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Objectives This study investigated late toxicity and infield progression-free survival in patients with locally recurrent rectal cancer (LRRC) who had previously received irradiation to the pelvis. Methods Twenty-two patients were treated by reirradiation to the pelvis between January 2000 and August 2007. All patients received curative surgery with preoperative or postoperative chemoradiotherapy as an initial treatment. Five patients (23%) underwent surgical resection after reirradiation. The median follow-up duration was 20 months (range, 7-91 months). Results Two patients (9%) had grade-3 acute toxicity and eight patients (36%) had grade-3 to -4 late toxicity. The incidence of grade-3 to -4 late toxicity in the gastrointestinal and urinary system was 18% and 27%, respectively. Recurrent tumor location (axial or anterior) and surgical resection after reirradiation significantly influenced severe late toxicity (P=0.024 and P=0.039, respectively). In the 17 patients not undergoing surgery after reirradiation, median infield progression-free survival was 16 months. Reirradiation doses exceeding 50Gyαβ10 (equivalent dose in 2Gy fractions) significantly increased the infield progression-free survival (P=0.005). Conclusions Tumor location (axial or anterior) and surgery after reirradiation may increase severe late toxicity. In addition, an EQD2 exceeding 50Gyαβ10 may improve infield control.

AB - Objectives This study investigated late toxicity and infield progression-free survival in patients with locally recurrent rectal cancer (LRRC) who had previously received irradiation to the pelvis. Methods Twenty-two patients were treated by reirradiation to the pelvis between January 2000 and August 2007. All patients received curative surgery with preoperative or postoperative chemoradiotherapy as an initial treatment. Five patients (23%) underwent surgical resection after reirradiation. The median follow-up duration was 20 months (range, 7-91 months). Results Two patients (9%) had grade-3 acute toxicity and eight patients (36%) had grade-3 to -4 late toxicity. The incidence of grade-3 to -4 late toxicity in the gastrointestinal and urinary system was 18% and 27%, respectively. Recurrent tumor location (axial or anterior) and surgical resection after reirradiation significantly influenced severe late toxicity (P=0.024 and P=0.039, respectively). In the 17 patients not undergoing surgery after reirradiation, median infield progression-free survival was 16 months. Reirradiation doses exceeding 50Gyαβ10 (equivalent dose in 2Gy fractions) significantly increased the infield progression-free survival (P=0.005). Conclusions Tumor location (axial or anterior) and surgery after reirradiation may increase severe late toxicity. In addition, an EQD2 exceeding 50Gyαβ10 may improve infield control.

UR - http://www.scopus.com/inward/record.url?scp=84859889333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859889333&partnerID=8YFLogxK

U2 - 10.1002/jso.23023

DO - 10.1002/jso.23023

M3 - Article

C2 - 22213210

AN - SCOPUS:84859889333

VL - 105

SP - 637

EP - 642

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 7

ER -